Posted by Michael Wonder on 04 Feb 2019
UK patient activist group takes aim at Orkambi patent
4 February 2019 - Calls to bypass patent adds to pressure on Vertex.
Pressure is rising on Vertex on access to its cystic fibrosis (CF) drug Orkambi in the UK, with an MP today calling for the government to bypass its patent and provide cheap access to the treatment.
Vertex has been locked in a row with NHS England over Orkambi’s price for three years, and CF campaigners say patients who would have benefitted from the treatment in that time have now died.
